Researchers reported a new gene-activation approach designed to work inside the body, aiming to overcome a key limitation of CRISPR-based tuning: delivery. The work describes a gene-activation tool engineered to adjust expression of protective versus harmful genes within human cells, while addressing packaging constraints that can limit in vivo CRISPR delivery. The article frames the technology around the challenge of getting precise genetic regulation into target tissues with therapeutically feasible delivery methods. It suggests the strategy could broaden where gene-expression modulation is realistically achievable. As gene regulators increasingly compete to demonstrate in vivo deliverability, the tool’s core value proposition is reducing delivery size without losing functional control of gene expression.